4 months ago
MLYS
AnalystsGreg HarrisonGreg Harrison's Stock Forecasts
AnalystsGreg Harrison
Analyst Ranking
Top 6%
#308 out of 5312 analysts
Average Return
+29.25%
Win Rate
62%52 out of 84
Risk vs Reward
Poor
Good
Greg Harrison's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Liquidia CorpLQDA | +337.57% | $14.18 | $62.03 | 2025-05-28 - 2026-05-27 | Buy |
Travere Therapeutics IncTVTX | +248.02% | $16.91 | $58.85 | 2025-08-07 - 2026-06-26 | Buy |
Iveric Bio IncISEE | +244.89% | $11.25 | $38.80 | 2022-06-08 - 2023-06-07 | Strong Buy |
Bridgebio Pharma IncBBIO | +179.89% | $23.72 | $66.39 | 2024-11-15 - 2025-11-14 | Buy |
Bridgebio Pharma IncBBIO | +161.09% | $27.19 | $70.99 | 2024-11-25 - 2025-11-24 | Buy |
Greg Harrison Analyst Color
Get additional color on Greg Harrison's coverage of popular stocks
10 months ago
MLYS
3 years ago
NTLA
Greg Harrison's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Agios Pharmaceuticals IncAGIO | 11 | Strong Buy | $40.00 | +5.54% | Maintains | a month ago |
United Therapeutics CorpUTHR | 5 | Hold | $626.00 | +15.36% | Maintains | 3 months ago |
Mineralys Therapeutics IncMLYS | 3 | Strong Buy | $51.00 | +91.15% | Maintains | 4 months ago |
Vertex Pharmaceuticals IncVRTX | 8 | Hold | $558.00 | +13.57% | Maintains | 5 months ago |
Intellia Therapeutics IncNTLA | 3 | Strong Buy | $30.00 | +79.86% | Maintains | 8 months ago |
Travere Therapeutics IncTVTX | 6 | Buy | $31.00 | -47.32% | Maintains | a year ago |
Ocular Therapeutix IncOCUL | 2 | Buy | $20.00 | +103.25% | Maintains | a year ago |
Bridgebio Pharma IncBBIO | 7 | Buy | $57.00 | -18.85% | Maintains | a year ago |
Alnylam Pharmaceuticals IncALNY | 6 | Buy | $450.00 | +54.44% | Maintains | a year ago |
Gossamer Bio IncGOSS | 1 | Buy | $11.00 | +6,906.37% | Initiates Coverage On | a year ago |
Arcturus Therapeutics Holdings IncARCT | 2 | Buy | $35.00 | +408.72% | Maintains | a year ago |
Rocket Pharmaceuticals IncRCKT | 6 | Buy | $19.00 | N/A | Maintains | a year ago |
Liquidia CorpLQDA | 6 | Buy | $37.00 | N/A | Maintains | a year ago |
Keros Therapeutics IncKROS | 6 | Buy | $26.00 | N/A | Maintains | a year ago |
Vera Therapeutics IncVERA | 2 | Buy | $55.00 | N/A | Maintains | a year ago |
Apellis Pharmaceuticals IncAPLS | 4 | Hold | $20.00 | N/A | Maintains | a year ago |
Geron CorpGERN | 3 | Hold | $1.50 | N/A | Downgrades | a year ago |
Beam Therapeutics IncBEAM | 5 | Buy | $40.00 | N/A | Upgrades | a year ago |
Disc Medicine IncIRON | 4 | Buy | $75.00 | N/A | Maintains | a year ago |
Eyepoint IncEYPT | 1 | Buy | $18.00 | N/A | Initiates Coverage On | 2 years ago |
Stoke Therapeutics IncSTOK | 3 | Hold | $12.00 | N/A | Upgrades | 3 years ago |
Sangamo Therapeutics IncSGMO | 1 | Sell | $1.50 | N/A | Downgrades | 3 years ago |
Editas Medicine IncEDIT | 2 | Hold | $15.00 | N/A | Maintains | 4 years ago |
Omeros CorpOMER | 1 | Sell | $3.00 | N/A | Downgrades | 4 years ago |
Senti Biosciences Holdings IncSNTI | 1 | Strong Buy | $70.00 | N/A | Initiates Coverage On | 4 years ago |
Neurogene IncNGNE | 2 | Sell | $5.00 | N/A | Downgrades | 4 years ago |
Radius Health IncRDUS1 | 1 | Hold | $8.00 | N/A | Upgrades | 4 years ago |
Iveric Bio IncISEE | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 4 years ago |
Athersys IncATHXQ | 4 | Sell | $6.25 | N/A | Downgrades | 4 years ago |
Sentinelone IncS | 1 | Strong Buy | $54.00 | N/A | Maintains | 4 years ago |
Nektar TherapeuticsNKTR | 5 | Sell | $90.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.